BCL10 Mutants: Architects of Oncogenic Signaling Provide a Blueprint for Precision Medicine.

BCL10, a key activator of NF-κB downstream of oncogenic B-cell receptor signaling, is mutated in nearly 40% of the BN2/C1 genetic subtype of diffuse large B-cell lymphoma, but how these mutations function to augment signaling and their relevance to targeted precision medicine agents remains unclear. In this issue of Cancer Discovery, Xia and colleagues demonstrate distinct mechanisms of oncogenic signaling regulation and therapeutic vulnerabilities among different recurrent BCL10 mutations. See related article by Xia et al., p. 1922 (1). ©2022 American Association for Cancer Research.

Citation

James D Phelan, Thomas Oellerich. BCL10 Mutants: Architects of Oncogenic Signaling Provide a Blueprint for Precision Medicine. Cancer discovery. 2022 Aug 05;12(8):1844-1846

Mesh Tags

Substances

PMID: 35929131

search → result